Home » Topics » Immune, BioWorld Science

Immune, BioWorld Science
RSS

Boston Life Sciences licenses BCLx-gamma gene from Harvard

March 10, 1998

Zenapax approved in Switzerland

March 5, 1998

Vaccines for group B meningococcal infection disclosed

March 4, 1998

Cholera toxin enhances transcutaneous delivery, enabling development of needle-free vaccines

March 4, 1998

NIH offers potential tuberculosis vaccine technology for licensing

March 3, 1998

NIH offers new technology for licensing

March 2, 1998

First potent and selective CB2 receptor antagonist developed at Sanofi

Feb. 24, 1998

Pneumovax does not prevent pneumonia in middle-aged and elderly immunocompetent patients

Feb. 19, 1998

Cytokine-inducing profile of imiquimod and two analogues characterized in monkeys

Feb. 19, 1998

Zenapax uveitis and transplant trial data reported

Feb. 19, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
mRNA flu vaccine can activate broad germinal center response
BioWorld
On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...